Novartis Radioligand Therapy Launch in Belgium

Bringing innovative prostate cancer therapy to Belgium first and designing the national model that could scale.

The context.

Launching an innovative therapy is more than a brand strategy. RLT is logistically complex: it combines pharmaceutical and nuclear medicine workflows, requires coordination across hospitals, identifies eligible patients far upstream of treatment, and operates in a regulatory and payment environment built for traditional therapies. Belgium had the opportunity to be a European first mover but only if patient flow and product flow were designed before launch, not improvised after.

What made the difference.

As part of Novartis Belux, I supported the launch through:

• Patient flow mapping

• Product flow mapping

Principle.

Operational excellence and access strategy designed together — not handed across at launch.

Stakeholders aligned.

Novartis Belux • prescribing oncologists and urologists • hospitals and nuclear medicine departments • RIZIV/INAMI • patient organisations

Outcome.

Belgium became a European leader in RLT delivery — with increased speed and quality of patient access, and a national model that could be referenced beyond the Belgian launch.